[Pharmacokinetics of ceftazidime in cystic fibrosis]
A Saint Raymond1, P Genillier, G Lenoir
1Service du Pr J. Rey, Hôpital des Enfants malades, Paris.
Abstract:
Ceftazidime has been recognized as an invaluable antibiotic for the treatment of lower respiratory infections in patients with cystic fibrosis. In these patients the apparent volume of distribution of ceftazidime is increased. Its clearance is besides increased, with a significant reduction in the area under concentrations curve. The distribution of ceftazidime in the bronchi seems to be very satisfactory. It results from these data that dosage in children with cystic fibrosis may reach 200 to 300 mg/kg/day divided into 3 or 4 injections. The intrabronchial administration of ceftazidime has not proved effective.
More Related Videos
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Measurement of Bioavailability: Pharmacokinetic Methods
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacodynamic Models: Overview


